SYS-CON MEDIA Authors: Mat Mathews, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

Prima BioMed to Host Investor Days in Australia

SYDNEY, AUSTRALIA -- (Marketwire) -- 01/23/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") is pleased to announce upcoming investor days at several major Australian cities in February.

Prima CEO, Matthew Lehman will host the sessions, to be held in Sydney, Melbourne, Brisbane and Perth, in the week commencing 4 February 2013.

Mr. Lehman will provide an update on the Company's business and attendees will have an opportunity for Q&A.

Details of dates and venues are provided below.

Perth
Monday, 4
th February
Parmelia Hilton Hotel, 14 Mill St, Perth
10.00am - 11.30am local time

Melbourne
Tuesday, 5
th February
Westin Melbourne Hotel, 205 Collins St, Melbourne
10.30am - 12.00noon local time

Brisbane
Wednesday, 6
th February
Hilton Brisbane Hotel, 190 Elizabeth St, Brisbane
10.00am - 11.30am local time

Sydney
Thursday, 7
th February
Radisson Blu Hotel, 27 O'Connell St, Sydney
10.30am - 12.00noon local time

Shareholders and other interested parties are kindly requested to help assure appropriate accommodations by sending an RSVP by email to [email protected] and identify the city of attendance by Friday 1st February.

About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.

For further information please contact:

USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Email Contact

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.